The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Stryker's revenues will grow 1.9% and EPS will grow 2.0%.
The average estimate for revenue is $2.20 billion. On the bottom line, the average EPS estimate is $1.01.
Last quarter, Stryker logged revenue of $2.34 billion. GAAP reported sales were 5.6% higher than the prior-year quarter's $2.22 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.14. GAAP EPS of $0.71 for Q4 were 32% lower than the prior-year quarter's $1.04 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 68.3%, 100 basis points better than the prior-year quarter. Operating margin was 17.8%, 630 basis points worse than the prior-year quarter. Net margin was 11.5%, 660 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $8.99 billion. The average EPS estimate is $4.32.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,427 members out of 1,459 rating the stock outperform, and 32 members rating it underperform. Among 437 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 431 give Stryker a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stryker is outperform, with an average price target of $59.68.
Is Stryker the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Stryker to My Watchlist.